Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03221842 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients
A Phase 3 study, sponsored by CSL Behring.
- Terminated
- Registry status
- Phase 3
- Development phase
- 63
- Enrollment target
NCT03221842 is a Phase 3 study that was terminated before completion, run by CSL Behring. The registered enrollment target is 63 participants.
The verdict
NCT03221842, a Phase 3 study, was terminated before completion, sponsored by CSL Behring.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 63 participants
- Enrollment target
Study Summary
This is a double-blind, randomized-withdrawal, placebo-controlled study in kidney transplant patients with AMR to evaluate the efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care (IVIG).
Interventions
- DRUG Placebo
- DRUG C1-esterase inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2017-11-06 |
| Est. Completion | 2021-01-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03221842
The ClinicalTrials.gov registry entry for NCT03221842 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03221842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03221842 about?
NCT03221842 is a clinical study titled "Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients". This is a double-blind, randomized-withdrawal, placebo-controlled study in kidney transplant patients with AMR to evaluate the efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care (IVIG).
What is the current status of trial NCT03221842?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 63 participants. The study started on 2017-11-06. Estimated completion is 2021-01-20.
What interventions are being tested in trial NCT03221842?
The interventions under investigation include: Placebo (DRUG), C1-esterase inhibitor (DRUG).
Who is sponsoring clinical trial NCT03221842?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.